Test ID: MENMS
Multiple Endocrine Neoplasia Type 2 (2A, 2B, FMTC) Mutation Screen
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
80573
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Conditional
Useful For Suggests clinical disorders or settings where the test may be helpful
Confirmation of diagnosis of multiple endocrine neoplasia type 2 (MEN 2), MEN 2B, and familial medullary thyroid carcinoma (FMTC)
Documentation of germline mutation to distinguish FMTC from sporadic multifocal medullary thyroid carcinoma
Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request
Includes sequencing of the following exons: 10, 11, 13-16.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing of Exons 10, 11, 13, 14, 15, and 16 of the RET Proto-onocogene
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
MEN2 (2A,2B,FMTC) Mutation Screen
Aliases Lists additional common names for a test, as an aid in searching
Endocrine Cancer Syndrome
Familial Medullary Thyroid Carcinoma
FMTC
MEN2A
MEN2B
Multiple Endocrine Neoplasia Type 2A
Multiple Endocrine Neoplasia Type 2B
RET proto-oncogene (see Q&A for more info)
Familial Medullary Thyroid Carcinoma
FMTC
MEN2A
MEN2B
Multiple Endocrine Neoplasia Type 2A
Multiple Endocrine Neoplasia Type 2B
RET proto-oncogene (see Q&A for more info)
External
link
PDF
document
Excel
document
Word
document